TP 452Alternative Names: DPA free fatty acid - Thetis; DPA-FFA – Thetis
Latest Information Update: 08 Feb 2016
At a glance
- Originator Thetis Pharmaceuticals
- Class Antihyperlipidaemics; Omega 3 fatty acids
- Mechanism of Action HMG-CoA reductase inhibitors; PCSK9 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypercholesterolaemia